How to Buy marksans Shares on Fincept?
You can buy Marksans Pharma Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Marksans Pharma Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Marksans, including updates on board meetings and corporate actions.
Marksans Pharma Limited - https://marksanspharma.com
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. It also produces a range of solid oral dosage forms, including tablets and hard gelatin capsules; soft gels; essential oils; ointments; and creams and liquids, as well as prescription drugs. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Marksans Pharma Limited Share Price Today
236.55
OPEN
249.25
HIGH
236.40
LOW
240.55
CLOSE
1,019 K
VOLUME
13,672 Cr
Market Cap
2461882
Average Volume
Healthcare
Sector
NSI
Exchange
Marksans Pharma Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: MARKSANS Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Marksans Pharma Limited |
MARKSANS |
INE750C01026 |
Dividend - Rs 0.60 Per Share |
17 Sep 2024 |
1 |
N/A |
Marksans Pharma Limited |
MARKSANS |
INE750C01026 |
Dividend - Re 0.50 Per Share |
07 Jun 2023 |
1 |
N/A |
Marksans Pharma Limited |
MARKSANS |
INE750C01026 |
Annual General Meeting/Dividend - Rs 0.25 Per Share |
19 Aug 2022 |
1 |
N/A |
Marksans Pharma Limited |
MARKSANS |
INE750C01026 |
Annual General Meeting/Dividend - Rs 0.25 Per Share |
15 Sep 2021 |
1 |
N/A |
Marksans Pharma Limited |
MARKSANS |
INE750C01026 |
Extra-Ordinary General Meeting |
01 Jul 2021 |
1 |
N/A |
NSE: MARKSANS Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
MARKSANS |
02 Jan 2025, 11:55:50 |
Trading Window-XBRL |
Pharmaceuticals |
MARKSANS |
30 Dec 2024, 11:37:18 |
Trading Window |
Pharmaceuticals |
MARKSANS |
11 Dec 2024, 12:48:13 |
Analysts/Institutional Investor Meet/Con. Call Updates |
Pharmaceuticals |
MARKSANS |
25 Nov 2024, 10:30:10 |
Analysts/Institutional Investor Meet/Con. Call Updates |
Pharmaceuticals |
MARKSANS |
22 Nov 2024, 12:03:24 |
Press Release |
Pharmaceuticals |
NSE: MARKSANS Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Marksans Pharma Limited |
MARKSANS |
13 Jan 2025, 12:52:00 |
13 Jan 2025, 12:52:00 |
|
Marksans Pharma Limited |
MARKSANS |
17 Oct 2024, 14:52:00 |
17 Oct 2024, 14:52:00 |
|
Marksans Pharma Limited |
MARKSANS |
12 Jul 2024, 16:26:00 |
12 Jul 2024, 16:26:00 |
|
Marksans Pharma Limited |
MARKSANS |
19 Apr 2024, 10:30:00 |
19 Apr 2024, 11:00:00 |
|
Marksans Pharma Limited |
MARKSANS |
12 Feb 2024, 13:45:00 |
12 Feb 2024, 14:15:00 |
NSE: MARKSANS Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson Related To Promoters,Executive Director-CEO-MD |
18 Aug 1972 |
06 Oct 2005 |
00020983 |
MARK SALDANHA |
Active |
Executive Director |
11 Dec 1971 |
25 Sep 2014 |
00021023 |
SANDRA SALDANHA |
Active |
Executive Director |
14 Oct 1969 |
24 Jan 2019 |
08338573 |
VARDDHMAN VIKRAMADITYA JAIN |
Active |
Independent Director |
01 Oct 1951 |
01 Apr 2015 |
03630668 |
SEETHARAMA RAJU BUDDHARAJU |
Active |
Independent Director |
23 Sep 1972 |
14 Mar 2018 |
00212589 |
DIGANT MAHESH PARIKH |
Active |
NSE: MARKSANS Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
MARKSANS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2024 . |
MARKSANS |
N/A |
INE750C01026 |
Marksans Pharma Limited |
23 Oct 2024, 15:36:03 |
Financial Results |
MARKSANS |
N/A |
INE750C01026 |
Marksans Pharma Limited |
31 Jul 2024, 10:50:24 |
Financial Results/Dividend |
MARKSANS |
N/A |
INE750C01026 |
Marksans Pharma Limited |
13 May 2024, 14:26:53 |
Financial Results |
MARKSANS |
N/A |
INE750C01026 |
Marksans Pharma Limited |
17 Jan 2024, 12:09:03 |
MARKSANS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 09-Nov-2023 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2023 . |
MARKSANS |
N/A |
INE750C01026 |
Marksans Pharma Limited |
27 Oct 2023, 18:07:02 |
NSE: MARKSANS Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results |
MARKSANS |
- |
INE750C01026 |
Marksans Pharma Limited |
23 Oct 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 |
Financial Results |
MARKSANS |
- |
INE750C01026 |
Marksans Pharma Limited |
31 Jul 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 |
Financial Results/Dividend |
MARKSANS |
- |
INE750C01026 |
Marksans Pharma Limited |
13 May 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024 and dividend |
Financial Results |
MARKSANS |
- |
INE750C01026 |
Marksans Pharma Limited |
17 Jan 2024, 00:00:00 |
To consider and approve the financial results for the period ended December 31, 2023 |
Financial Results |
MARKSANS |
- |
INE750C01026 |
Marksans Pharma Limited |
27 Oct 2023, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2023 |
NSE: MARKSANS Balance Sheet Data In (Cr)
| date | period_type | Treasury Shares Number | Ordinary Shares Number | Share Issued | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Preferred Securities Outside Stock Equity | Non Current Pension And Other Postretirement Benefit Plans | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Deferred Taxes Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Non Current Deferred Taxes Assets | Investmentin Financial Assets | Available For Sale Securities | Goodwill And Other Intangible Assets | Other Intangible Assets | Goodwill | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Hedging Assets Current | Restricted Cash | Prepaid Assets | Inventory | Finished Goods | Work In Process | Raw Materials | Other Receivables | Taxes Receivable | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 0.00 | 453,163,746.00 | 453,163,746.00 | 1,982,890,000.00 | 21,690,780,000.00 | 23,054,320,000.00 | 16,343,660,000.00 | 21,690,780,000.00 | 1,742,540,000.00 | 22,813,970,000.00 | 22,813,970,000.00 | 23,051,180,000.00 | 237,210,000.00 | 22,813,970,000.00 | 22,360,810,000.00 | 0.00 | 0.00 | 453,160,000.00 | 453,160,000.00 | 6,061,990,000.00 | 1,620,580,000.00 | 0.00 | 0.00 | 25,590,000.00 | 1,551,430,000.00 | 1,551,430,000.00 | 0.00 | 43,560,000.00 | 4,441,410,000.00 | 314,990,000.00 | 0.00 | 431,460,000.00 | 191,110,000.00 | 240,350,000.00 | 18,460,000.00 | 3,124,720,000.00 | 0.00 | 0.00 | 308,270,000.00 | 2,816,450,000.00 | 29,113,170,000.00 | 8,328,100,000.00 | 322,910,000.00 | 0.00 | 0.00 | 9,960,000.00 | 9,960,000.00 | 1,123,190,000.00 | 713,750,000.00 | 409,440,000.00 | 6,860,930,000.00 | 0.00 | 6,860,930,000.00 | 111,860,000.00 | 6,749,070,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20,785,070,000.00 | 715,600,000.00 | 0.00 | 0.00 | 0.00 | 7,583,530,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 145,720,000.00 | 5,524,770,000.00 | 0.00 | 0.00 | 6,815,450,000.00 | 3,005,780,000.00 | 3,809,670,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 0.00 | 453,163,746.00 | 453,163,746.00 | 2,440,610,000.00 | 19,607,930,000.00 | 20,941,450,000.00 | 14,726,430,000.00 | 19,607,930,000.00 | 2,149,700,000.00 | 20,650,540,000.00 | 20,650,540,000.00 | 20,859,060,000.00 | 208,520,000.00 | 20,650,540,000.00 | 20,197,380,000.00 | 10,689,290,000.00 | 5,186,450,000.00 | 453,160,000.00 | 453,160,000.00 | 5,950,470,000.00 | 2,051,980,000.00 | 0.00 | 0.00 | 106,200,000.00 | 1,900,190,000.00 | 1,900,190,000.00 | 0.00 | 45,590,000.00 | 3,898,490,000.00 | 9,040,000.00 | 199,080,000.00 | 540,420,000.00 | 249,510,000.00 | 290,910,000.00 | 19,550,000.00 | 3,109,180,000.00 | 423,010,000.00 | 3,400,000.00 | 199,080,000.00 | 2,682,770,000.00 | 26,809,530,000.00 | 8,184,610,000.00 | 293,790,000.00 | 197,000,000.00 | 0.00 | 1,680,000.00 | 1,680,000.00 | 1,042,610,000.00 | 647,620,000.00 | 394,990,000.00 | 6,932,210,000.00 | -3,003,750,000.00 | 9,935,960,000.00 | 175,110,000.00 | 6,757,100,000.00 | 4,704,380,000.00 | 4,826,880,000.00 | 229,590,000.00 | 0.00 | 18,624,920,000.00 | 120,150,000.00 | 1,100,000.00 | 338,970,000.00 | 344,560,000.00 | 6,179,440,000.00 | 3,308,570,000.00 | 248,000,000.00 | 2,622,870,000.00 | 57,440,000.00 | 49,180,000.00 | 4,531,770,000.00 | -52,680,000.00 | 4,584,450,000.00 | 7,002,310,000.00 | 2,969,540,000.00 | 4,032,770,000.00 | 2,512,090,000.00 | 1,520,680,000.00 |
| 2024-03-31T00:00:00 | annual | 0.00 | 453,163,746.00 | 453,163,746.00 | 2,440,610,000.00 | 19,607,930,000.00 | 20,941,450,000.00 | 14,726,430,000.00 | 19,607,930,000.00 | 2,149,700,000.00 | 20,650,540,000.00 | 20,650,540,000.00 | 20,859,060,000.00 | 208,520,000.00 | 20,650,540,000.00 | 20,197,380,000.00 | 10,689,290,000.00 | 5,186,450,000.00 | 453,160,000.00 | 453,160,000.00 | 5,950,470,000.00 | 2,051,980,000.00 | 0.00 | 0.00 | 106,200,000.00 | 1,900,190,000.00 | 1,900,190,000.00 | 0.00 | 45,590,000.00 | 3,898,490,000.00 | 9,040,000.00 | 199,080,000.00 | 540,420,000.00 | 249,510,000.00 | 290,910,000.00 | 19,550,000.00 | 3,109,180,000.00 | 423,010,000.00 | 3,400,000.00 | 199,080,000.00 | 2,682,770,000.00 | 26,809,530,000.00 | 8,184,610,000.00 | 293,790,000.00 | 197,000,000.00 | 0.00 | 1,680,000.00 | 1,680,000.00 | 1,042,610,000.00 | 647,620,000.00 | 394,990,000.00 | 6,932,210,000.00 | -3,003,750,000.00 | 9,935,960,000.00 | 175,110,000.00 | 6,757,100,000.00 | 4,704,380,000.00 | 4,826,880,000.00 | 229,590,000.00 | 0.00 | 18,624,920,000.00 | 120,150,000.00 | 1,100,000.00 | 338,970,000.00 | 344,560,000.00 | 6,179,440,000.00 | 3,308,570,000.00 | 248,000,000.00 | 2,622,870,000.00 | 57,440,000.00 | 49,180,000.00 | 4,531,770,000.00 | -52,680,000.00 | 4,584,450,000.00 | 7,002,310,000.00 | 2,969,540,000.00 | 4,032,770,000.00 | 2,512,090,000.00 | 1,520,680,000.00 |
| 2023-09-30T00:00:00 | quarterly | 6,474,276.00 | 446,689,470.00 | 453,163,746.00 | 1,111,030,000.00 | 17,681,460,000.00 | 19,108,000,000.00 | 13,707,840,000.00 | 17,681,460,000.00 | 758,940,000.00 | 18,755,910,000.00 | 18,755,910,000.00 | 18,970,120,000.00 | 214,210,000.00 | 18,755,910,000.00 | 18,302,750,000.00 | 0.00 | 0.00 | 453,160,000.00 | 453,160,000.00 | 4,165,630,000.00 | 838,240,000.00 | 0.00 | 0.00 | 167,270,000.00 | 610,490,000.00 | 610,490,000.00 | 0.00 | 60,480,000.00 | 3,327,390,000.00 | 264,220,000.00 | 0.00 | 500,540,000.00 | 148,450,000.00 | 352,090,000.00 | 24,050,000.00 | 2,417,890,000.00 | 0.00 | 0.00 | 414,550,000.00 | 2,003,340,000.00 | 23,135,750,000.00 | 6,100,520,000.00 | 272,790,000.00 | 0.00 | 0.00 | 32,130,000.00 | 32,130,000.00 | 1,074,450,000.00 | 687,430,000.00 | 387,020,000.00 | 4,712,450,000.00 | 0.00 | 4,712,450,000.00 | 187,930,000.00 | 4,524,520,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17,035,230,000.00 | 503,310,000.00 | 0.00 | 0.00 | 0.00 | 5,306,030,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13,280,000.00 | 4,495,180,000.00 | 0.00 | 0.00 | 6,717,430,000.00 | 3,132,700,000.00 | 3,584,730,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 6,474,276.00 | 446,689,470.00 | 453,163,746.00 | 1,229,450,000.00 | 16,358,760,000.00 | 17,867,500,000.00 | 13,343,110,000.00 | 16,358,760,000.00 | 813,570,000.00 | 17,451,620,000.00 | 17,451,620,000.00 | 17,650,720,000.00 | 199,100,000.00 | 17,451,620,000.00 | 16,998,460,000.00 | 7,776,030,000.00 | 5,186,450,000.00 | 453,160,000.00 | 453,160,000.00 | 4,253,170,000.00 | 843,270,000.00 | 0.00 | 0.00 | 153,860,000.00 | 656,890,000.00 | 656,890,000.00 | 0.00 | 32,520,000.00 | 3,409,900,000.00 | 8,430,000.00 | 252,780,000.00 | 572,560,000.00 | 156,680,000.00 | 415,880,000.00 | 13,260,000.00 | 2,516,310,000.00 | 207,700,000.00 | 2,600,000.00 | 252,780,000.00 | 2,306,010,000.00 | 21,903,890,000.00 | 5,150,880,000.00 | 145,660,000.00 | 120,900,000.00 | 0.00 | 0.00 | 34,770,000.00 | 1,092,860,000.00 | 707,970,000.00 | 384,890,000.00 | 3,928,420,000.00 | -2,362,890,000.00 | 6,291,310,000.00 | 131,990,000.00 | 3,796,430,000.00 | 3,448,630,000.00 | 2,695,920,000.00 | 14,770,000.00 | 0.00 | 16,753,010,000.00 | 3,870,000.00 | 0.00 | 257,740,000.00 | 276,210,000.00 | 4,847,390,000.00 | 2,613,400,000.00 | 204,540,000.00 | 2,029,450,000.00 | 29,340,000.00 | 19,160,000.00 | 4,168,460,000.00 | -37,120,000.00 | 4,205,580,000.00 | 7,150,840,000.00 | 3,326,470,000.00 | 3,824,370,000.00 | 2,949,140,000.00 | 875,230,000.00 |
| 2023-03-31T00:00:00 | annual | 6,474,276.00 | 446,689,470.00 | 453,163,746.00 | 1,229,450,000.00 | 16,358,760,000.00 | 17,867,500,000.00 | 13,343,110,000.00 | 16,358,760,000.00 | 813,570,000.00 | 17,451,620,000.00 | 17,451,620,000.00 | 17,650,720,000.00 | 199,100,000.00 | 17,451,620,000.00 | 16,998,460,000.00 | 7,776,030,000.00 | 5,186,450,000.00 | 453,160,000.00 | 453,160,000.00 | 4,253,170,000.00 | 843,270,000.00 | 0.00 | 0.00 | 153,860,000.00 | 656,890,000.00 | 656,890,000.00 | 0.00 | 32,520,000.00 | 3,409,900,000.00 | 8,430,000.00 | 252,780,000.00 | 572,560,000.00 | 156,680,000.00 | 415,880,000.00 | 13,260,000.00 | 2,516,310,000.00 | 207,700,000.00 | 2,600,000.00 | 252,780,000.00 | 2,306,010,000.00 | 21,903,890,000.00 | 5,150,880,000.00 | 145,660,000.00 | 120,900,000.00 | 0.00 | 0.00 | 34,770,000.00 | 1,092,860,000.00 | 707,970,000.00 | 384,890,000.00 | 3,928,420,000.00 | -2,362,890,000.00 | 6,291,310,000.00 | 131,990,000.00 | 3,796,430,000.00 | 3,448,630,000.00 | 2,695,920,000.00 | 14,770,000.00 | 0.00 | 16,753,010,000.00 | 3,870,000.00 | 0.00 | 257,740,000.00 | 276,210,000.00 | 4,847,390,000.00 | 2,613,400,000.00 | 204,540,000.00 | 2,029,450,000.00 | 29,340,000.00 | 19,160,000.00 | 4,168,460,000.00 | -37,120,000.00 | 4,205,580,000.00 | 7,150,840,000.00 | 3,326,470,000.00 | 3,824,370,000.00 | 2,949,140,000.00 | 875,230,000.00 |
| 2022-03-31T00:00:00 | annual | 0.00 | 409,313,698.00 | 409,313,698.00 | 1,107,780,000.00 | 11,136,760,000.00 | 12,435,620,000.00 | 8,449,820,000.00 | 11,136,760,000.00 | 694,860,000.00 | 12,022,700,000.00 | 12,022,700,000.00 | 12,229,710,000.00 | 207,010,000.00 | 12,022,700,000.00 | 931,000,000.00 | 5,093,090,000.00 | 1,816,870,000.00 | 409,310,000.00 | 409,310,000.00 | 4,171,290,000.00 | 609,110,000.00 | 0.00 | 0.00 | 176,210,000.00 | 414,340,000.00 | 414,340,000.00 | 0.00 | 18,560,000.00 | 3,562,180,000.00 | 543,980,000.00 | 173,270,000.00 | 693,440,000.00 | 280,520,000.00 | 412,920,000.00 | 7,240,000.00 | 2,126,860,000.00 | 123,770,000.00 | 2,300,000.00 | 173,270,000.00 | 2,000,790,000.00 | 16,401,000,000.00 | 4,389,000,000.00 | 15,540,000.00 | 26,080,000.00 | 38,570,000.00 | 26,080,000.00 | 26,080,000.00 | 885,940,000.00 | 585,690,000.00 | 300,250,000.00 | 3,438,410,000.00 | -2,044,130,000.00 | 5,482,540,000.00 | 22,490,000.00 | 3,415,920,000.00 | 3,188,310,000.00 | 2,257,400,000.00 | 14,340,000.00 | 0.00 | 12,012,000,000.00 | 25,220,000.00 | 70,610,000.00 | 30,070,000.00 | 183,270,000.00 | 4,244,420,000.00 | 2,628,100,000.00 | 106,970,000.00 | 1,509,350,000.00 | 13,150,000.00 | 30,550,000.00 | 3,947,780,000.00 | -26,970,000.00 | 3,974,750,000.00 | 3,466,930,000.00 | 4,350,000.00 | 3,462,580,000.00 | 1,895,720,000.00 | 1,566,860,000.00 |
| 2021-03-31T00:00:00 | annual | 0.00 | 409,313,698.00 | 409,313,698.00 | 341,030,000.00 | 8,194,730,000.00 | 9,052,350,000.00 | 6,038,520,000.00 | 8,194,730,000.00 | 153,630,000.00 | 8,864,950,000.00 | 8,864,950,000.00 | 9,053,520,000.00 | 188,570,000.00 | 8,864,950,000.00 | 8,455,640,000.00 | 3,349,270,000.00 | 1,836,320,000.00 | 409,310,000.00 | 409,310,000.00 | 3,234,670,000.00 | 245,000,000.00 | 50,000,000.00 | 0.00 | 80,630,000.00 | 93,260,000.00 | 93,260,000.00 | 0.00 | 21,110,000.00 | 2,989,670,000.00 | 635,010,000.00 | 300,210,000.00 | 247,770,000.00 | 60,370,000.00 | 187,400,000.00 | 18,550,000.00 | 1,782,450,000.00 | 93,850,000.00 | 1,960,000.00 | 300,210,000.00 | 1,686,640,000.00 | 12,288,190,000.00 | 3,260,000,000.00 | 15,950,000.00 | 41,580,000.00 | 7,990,000.00 | 25,630,000.00 | 25,630,000.00 | 670,220,000.00 | 474,360,000.00 | 195,860,000.00 | 2,540,210,000.00 | -1,564,060,000.00 | 4,104,270,000.00 | 56,000,000.00 | 2,484,210,000.00 | 2,643,650,000.00 | 1,390,810,000.00 | 13,810,000.00 | 0.00 | 9,028,190,000.00 | 115,650,000.00 | 14,620,000.00 | 29,050,000.00 | 9,770,000.00 | 4,043,200,000.00 | 2,716,400,000.00 | 147,620,000.00 | 1,179,180,000.00 | 1,020,000.00 | 0.00 | 2,719,490,000.00 | 0.00 | 2,719,490,000.00 | 2,095,390,000.00 | 2,610,000.00 | 2,092,780,000.00 | 1,576,800,000.00 | 515,980,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 50,000,000.00 | 14,745,756.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6,341,730.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: MARKSANS Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repurchase Of Capital Stock | Repayment Of Debt | Issuance Of Debt | Issuance Of Capital Stock | Capital Expenditure | End Cash Position | Beginning Cash Position | Effect Of Exchange Rate Changes | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Preferred Stock Issuance | Preferred Stock Payments | Net Common Stock Issuance | Common Stock Payments | Common Stock Issuance | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Short Term Debt Payments | Short Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Dividends Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net Business Purchase And Sale | Purchase Of Business | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Provisionand Write Offof Assets | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Pension And Employee Benefit Expense | Gain Loss On Investment Securities | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 215,690,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2,088,380,000.00 | 4,032,770,000.00 | 3,824,370,000.00 | 0.00 | 208,400,000.00 | -687,270,000.00 | 0.00 | -51,720,000.00 | -226,580,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -124,970,000.00 | -124,970,000.00 | 0.00 | 0.00 | -1,408,400,000.00 | 0.00 | 308,670,000.00 | 0.00 | 362,770,000.00 | 732,780,000.00 | -370,010,000.00 | 0.00 | 0.00 | -2,079,840,000.00 | 8,540,000.00 | -2,088,380,000.00 | 2,304,070,000.00 | -1,223,490,000.00 | -1,261,920,000.00 | 526,890,000.00 | -290,410,000.00 | 0.00 | -1,126,730,000.00 | -371,670,000.00 | -225,840,000.00 | 51,570,000.00 | 742,700,000.00 | 0.00 | 742,700,000.00 | 0.00 | -43,630,000.00 | 30,360,000.00 | -940,000.00 | 4,235,250,000.00 |
| 2023-03-31T00:00:00 | annual | 1,837,810,000.00 | -451,660,000.00 | 0.00 | 52,960,000.00 | 2,747,090,000.00 | -536,310,000.00 | 3,824,370,000.00 | 2,064,060,000.00 | 20,000.00 | 1,760,290,000.00 | 1,978,290,000.00 | 0.00 | -60,660,000.00 | -101,710,000.00 | 0.00 | -50,000,000.00 | -50,000,000.00 | 2,345,430,000.00 | -401,660,000.00 | 2,747,090,000.00 | 52,960,000.00 | 52,960,000.00 | 0.00 | 52,960,000.00 | -2,592,120,000.00 | 0.00 | 104,180,000.00 | 0.00 | -1,897,660,000.00 | 0.00 | -1,897,660,000.00 | -266,100,000.00 | -266,100,000.00 | -532,540,000.00 | 3,770,000.00 | -536,310,000.00 | 2,374,120,000.00 | -630,140,000.00 | -1,114,650,000.00 | -167,800,000.00 | -223,170,000.00 | 224,230,000.00 | -448,500,000.00 | -275,180,000.00 | -28,440,000.00 | 143,610,000.00 | 518,530,000.00 | 104,840,000.00 | 518,530,000.00 | 0.00 | 108,020,000.00 | -1,980,000.00 | 2,640,000.00 | 3,376,530,000.00 |
| 2022-03-31T00:00:00 | annual | 529,270,000.00 | 0.00 | 0.00 | 225,520,000.00 | 911,550,000.00 | -463,300,000.00 | 2,064,060,000.00 | 1,120,290,000.00 | 0.00 | 943,770,000.00 | 795,110,000.00 | 0.00 | -80,960,000.00 | -105,830,000.00 | 0.00 | 0.00 | 0.00 | 911,550,000.00 | 0.00 | 911,550,000.00 | 225,520,000.00 | 225,520,000.00 | 0.00 | 225,520,000.00 | -843,910,000.00 | 0.00 | 47,600,000.00 | 0.00 | -428,550,000.00 | 0.00 | -428,550,000.00 | 0.00 | 0.00 | -462,960,000.00 | 340,000.00 | -463,300,000.00 | 992,570,000.00 | -728,590,000.00 | -1,107,020,000.00 | -99,890,000.00 | -74,090,000.00 | 284,790,000.00 | -178,490,000.00 | -1,039,340,000.00 | 24,730,000.00 | 26,320,000.00 | 447,760,000.00 | 40,880,000.00 | 406,880,000.00 | 0.00 | -56,230,000.00 | -89,510,000.00 | 0.00 | 2,475,110,000.00 |
| 2021-03-31T00:00:00 | annual | 1,321,640,000.00 | 0.00 | -1,025,149.00 | 0.00 | 0.00 | -464,260,000.00 | 2,121,830,000.00 | 937,270,000.00 | 0.00 | 1,184,560,000.00 | -152,850,000.00 | 0.00 | -79,860,000.00 | -40,930,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1,030,000.00 | -1,030,000.00 | -1,025,149.00 | 0.00 | -448,490,000.00 | 0.00 | 10,570,000.00 | 283,460,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -459,060,000.00 | 5,200,000.00 | -464,260,000.00 | 1,785,900,000.00 | -485,300,000.00 | -1,316,100,000.00 | 0.00 | 25,750,000.00 | 417,840,000.00 | -1,392,250,000.00 | -367,440,000.00 | 68,270,000.00 | 0.00 | 361,510,000.00 | 117,600,000.00 | 243,910,000.00 | -2,624,087.00 | -16,250,000.00 | 9,670,000.00 | -370,000.00 | 3,021,640,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | -810,661,885.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5,488,183.00 | 0.00 | 0.00 | -295,032,467.00 | 0.00 | 0.00 | 0.00 | -50,000,000.00 | 0.00 | 0.00 | 0.00 | -810,661,885.00 | 0.00 | 0.00 | -34,475.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 665,730,552.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,514,400.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: MARKSANS Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Minority Interests | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | -0.17 | 0.00 | 509.66 | -0.66 | -0.66 | 313.70 | 74.27 | 1,094.24 | 509.00 | 434.73 | 22.58 | 11.20 | 33.79 | 314.19 | 313.70 | 1,784.73 | 12.24 | 45.32 | 45.32 | 0.00 | 0.00 | 313.70 | 313.70 | 0.00 | 313.70 | -1.20 | 314.90 | 314.90 | 108.63 | 423.53 | 3.90 | -5.02 | -0.13 | 5.16 | 22.58 | 0.00 | 11.20 | 33.79 | 389.46 | 690.49 | 168.54 | 74.27 | 12.30 | 61.97 | 145.01 | 127.31 | 17.70 | 12.24 | 1,079.96 | 1,094.24 | 2,174.20 | 2,174.20 |
| 2023-03-31T00:00:00 | annual | -5.45 | 0.00 | 420.68 | -25.43 | -25.43 | 266.31 | 51.85 | 958.08 | 395.25 | 343.40 | 2.91 | 5.75 | 12.04 | 286.29 | 266.31 | 1,536.72 | 12.92 | 41.54 | 41.54 | 0.00 | 0.00 | 266.31 | 266.31 | 0.00 | 266.31 | 0.99 | 265.32 | 265.32 | 72.33 | 337.65 | 7.49 | -14.63 | 0.26 | 14.36 | 2.91 | 3.38 | 5.75 | 12.04 | 312.90 | 578.64 | 127.57 | 51.85 | 10.48 | 41.37 | 149.45 | 133.19 | 16.26 | 12.92 | 891.54 | 958.08 | 1,849.62 | 1,849.62 |
| 2022-03-31T00:00:00 | annual | 0.76 | 0.00 | 294.57 | 3.11 | 3.11 | 184.57 | 44.78 | 716.82 | 297.68 | 252.90 | -2.47 | 5.39 | 5.97 | 182.22 | 184.57 | 1,263.39 | 4.74 | 40.93 | 40.93 | 0.00 | 0.00 | 184.57 | 184.57 | 0.00 | 184.57 | -2.25 | 186.81 | 186.81 | 60.70 | 247.51 | 9.56 | -2.52 | -0.12 | 2.63 | -2.47 | 3.06 | 5.39 | 5.97 | 216.74 | 546.57 | 153.58 | 44.78 | 4.09 | 40.69 | 133.88 | 119.05 | 14.84 | 4.74 | 763.31 | 716.82 | 1,480.12 | 1,480.12 |
| 2021-03-31T00:00:00 | annual | -2.66 | 0.00 | 354.41 | -12.63 | -12.63 | 238.54 | 36.15 | 618.60 | 341.78 | 305.63 | -6.83 | 3.47 | 1.16 | 248.51 | 238.54 | 1,049.66 | 12.31 | 40.93 | 40.93 | 0.00 | 0.00 | 238.54 | 238.54 | 0.00 | 238.54 | 0.00 | 238.54 | 238.54 | 63.63 | 302.16 | 3.87 | -14.25 | -0.03 | 14.28 | -6.83 | 4.52 | 3.47 | 1.16 | 318.71 | 431.06 | 59.60 | 36.15 | 11.76 | 24.39 | 133.49 | 109.61 | 23.88 | 12.31 | 749.78 | 618.60 | 1,368.37 | 1,368.37 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.78 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
5/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
7.65
P/E
39.43791
P/B
6.620584
Dividend Yield
0.21%
Market Cap
13,671.96 Cr.
Face Value
45.57
Book Value
45.57
ROE
14.72%
EBITDA Growth
488.68 Cr.
Debt/Equity
11.7
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of marksans?
The market capitalization of Marksans Pharma Limited is ₹13,672 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Marksans Pharma Limited?
The PE and PB ratios of Marksans Pharma Limited are Not Available and 6.620584 respectively as of 05 Feb 2025.
What is the 52 Week High of Marksans Pharma Limited?
The 52-week high of Marksans Pharma Limited is ₹358.7 as of 05 Feb 2025.
What is the 52 Week Low of Marksans Pharma Limited?
The 52-week low of Marksans Pharma Limited is ₹130 as of 05 Feb 2025.
What are the earnings per share (EPS) for Marksans Pharma Limited?
The Earnings Per Share (EPS) of Marksans Pharma Limited is ₹7.65 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Marksans Pharma Limited?
The Return on Equity (ROE) of Marksans Pharma Limited is 14.72% as per the most recent financial year data. Explore more on Fincept.